Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00042575 · ClinicalTrials.gov registry record · Phase 3
Dose Escalation, Double-Blind Treatment With Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in Major Depression
A Phase 3 study of Major Depressive Disorder, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
- 9
- Study locations
NCT00042575 is a Phase 3 study of Major Depressive Disorder that has completed, run by Eli Lilly and Company. The registered enrollment target is 120 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (68% lower). The trial reports 9 study locations across 9 states.
The verdict
NCT00042575, a Phase 3 study of Major Depressive Disorder, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
- 9
- Study locations
Study Summary
The Purposes of this Study are to determine: The safety of duloxetine and any side effects that might be associated with it. Whether duloxetine can help patients with major depression. It is possible that information collected during this study will be analyzed by the sponsor in the future to evaluate duloxetine for other possible uses or for other medical or scientific purposes other than those currently proposed. Duloxetine might not have any good effects for you.
Conditions Studied
Interventions
- DRUG Duloxetine
Study Locations (9)
Connecticut
- - Trumbull
Indiana
- - Lafayette
Maryland
- - Gaithersburg
Massachusetts
- - Belmont
Nebraska
- - Omaha
New Mexico
- - Albuquerque
New York
- - Staten Island
Utah
- - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2002-06 |
| Est. Completion | 2002-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00042575
The ClinicalTrials.gov registry entry for NCT00042575 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (68% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which Duloxetine is the first listed.
NCT00042575 reports 9 study locations spanning 9 distinct geographic areas - top geographies include Connecticut, Indiana, Maryland.
Frequently Asked Questions
What is clinical trial NCT00042575 about?
NCT00042575 is a clinical study titled "Dose Escalation, Double-Blind Treatment With Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in Major Depression". The Purposes of this Study are to determine: The safety of duloxetine and any side effects that might be associated with it. Whether duloxetine can help patients with major depression. It is possible that information collected during this study will be analyzed by the sponsor in the future to eva...
What is the current status of trial NCT00042575?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2002-06. Estimated completion is 2002-08.
What conditions does trial NCT00042575 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT00042575?
The interventions under investigation include: Duloxetine (DRUG).
Who is sponsoring clinical trial NCT00042575?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00042575 being conducted?
This trial has 9 study locations across Connecticut, Indiana, Maryland, Massachusetts, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
-
Study to Assess the Safety and Effectiveness of NMRA-335140-501
RECRUITING · Phase 3
-
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
-
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
RECRUITING · Phase 3
-
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
RECRUITING · Phase 3
-
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.